{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:43:59Z","timestamp":1790336639220,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40123-024-01002-0","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T04:01:37Z","timestamp":1722052897000},"page":"2445-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6686-4854","authenticated-orcid":false,"given":"Joel","family":"Uzzan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Bagijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insaf","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"issue":"2","key":"1002_CR1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","volume":"181","author":"LA Kim","year":"2012","unstructured":"Kim LA, D\u2019Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012;181(2):376\u20139. https:\/\/doi.org\/10.1016\/j.ajpath.2012.06.006.","journal-title":"Am J Pathol"},{"issue":"2","key":"1002_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.5.2.9","volume":"5","author":"JW Miller","year":"2016","unstructured":"Miller JW. VEGF: from discovery to therapy: the Champalimaud award lecture. Transl Vis Sci Technol. 2016;5(2):9. https:\/\/doi.org\/10.1167\/tvst.5.2.9.","journal-title":"Transl Vis Sci Technol"},{"issue":"8","key":"1002_CR3","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","volume":"16","author":"A Hang","year":"2023","unstructured":"Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals (Basel). 2023;16(8):1140. https:\/\/doi.org\/10.3390\/ph16081140.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"1002_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1208\/s12249-021-01949-4","volume":"22","author":"AC Parenky","year":"2021","unstructured":"Parenky AC, Wadhwa S, Chen HH, Bhalla AS, Graham KS, Shameem M. Container closure and delivery considerations for intravitreal drug administration. AAPS PharmSciTech. 2021;22(3):100. https:\/\/doi.org\/10.1208\/s12249-021-01949-4.","journal-title":"AAPS PharmSciTech"},{"key":"1002_CR5","unstructured":"Lucentis [package insert]. Genentech, Inc: South San Francisco, CA; 2024."},{"key":"1002_CR6","unstructured":"Eylea [package insert]. Regeneron Pharmaceuticals, Inc: Tarrytown, NY; 2023."},{"key":"1002_CR7","unstructured":"Beovu [package insert]. Novartis Pharmaceuticals Corporation: East Hanover, NJ; 2023."},{"key":"1002_CR8","unstructured":"Lucentis [summary of product characteristics]. Novartis Europharm Limited: Dublin, Ireland; 2023."},{"key":"1002_CR9","unstructured":"Eylea [summary of product characteristics]. Bayer AG: Leverkusen, Germany; 2024."},{"key":"1002_CR10","unstructured":"Beovu [summary of product characteristics]. Novartis Europharm Limited: Dublin, Ireland; 2024."},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/opth.S169044","volume":"13","author":"TM Sassalos","year":"2019","unstructured":"Sassalos TM, Paulus YM. Prefilled syringes for intravitreal drug delivery. Clin Ophthalmol. 2019;13:701\u20136. https:\/\/doi.org\/10.2147\/opth.S169044.","journal-title":"Clin Ophthalmol"},{"key":"1002_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350: g7647. https:\/\/doi.org\/10.1136\/bmj.g7647.","journal-title":"BMJ"},{"key":"1002_CR13","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. JBI; 2020.","DOI":"10.46658\/JBIRM-17-06"},{"issue":"10","key":"1002_CR14","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127\u201333. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099.","journal-title":"JBI Evid Synth"},{"issue":"3","key":"1002_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/XEB.0000000000000060","volume":"13","author":"A McArthur","year":"2015","unstructured":"McArthur A, Klug\u00e1rov\u00e1 J, Yan H, Florescu S. Innovations in the systematic review of text and opinion. Int J Evid Based Healthc. 2015;13(3):188\u201395. https:\/\/doi.org\/10.1097\/XEB.0000000000000060.","journal-title":"Int J Evid Based Healthc"},{"issue":"13","key":"1002_CR16","first-page":"1949","volume":"55","author":"JE Michaud","year":"2014","unstructured":"Michaud JE, Sigg J, Boado L, et al. Ranibizumab pre-filled syringe approved in the European Union: innovation to improve dose accuracy, reduce potential infection risk, and offer more efficient treatment administration. Invest Ophthalmol Vis Sci. 2014;55(13):1949.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"S1","key":"1002_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/ceo.12451","volume":"42","author":"C Woodcock","year":"2014","unstructured":"Woodcock C, Walsh M, Kurstjens N. Characteristics and potential benefits of the ranibizumab pre-filled syringe. Clin Exp Ophthalmol. 2014;42(S1):125. https:\/\/doi.org\/10.1111\/ceo.12451.","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"1002_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5301\/ejo.5000629","volume":"25","author":"E Souied","year":"2015","unstructured":"Souied E, Nghiem-Buffet S, Leteneux C, et al. Ranibizumab prefilled syringes: benefits of reduced syringe preparation times and less complex preparation procedures. Eur J Ophthalmol. 2015;25(6):529\u201334. https:\/\/doi.org\/10.5301\/ejo.5000629.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"1002_CR19","first-page":"A5214","volume":"63","author":"Y Subhi","year":"2016","unstructured":"Subhi Y, Kjer B, Munch IC. Prefilled syringes for intravitreal injection reduce preparation time. Dan Med J. 2016;63(4):A5214.","journal-title":"Dan Med J"},{"issue":"1","key":"1002_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000478717","volume":"58","author":"F Ayan","year":"2017","unstructured":"Ayan F, Jones C, Mohamed Q. Time differentiation for injection: ranibizumab vial vs pre-filled syringe (PFS) in real life clinical practice. Ophthalmic Res. 2017;58(1):2. https:\/\/doi.org\/10.1159\/000478717.","journal-title":"Ophthalmic Res"},{"issue":"12","key":"1002_CR21","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","volume":"136","author":"F Baudin","year":"2018","unstructured":"Baudin F, Benzenine E, Mariet AS, et al. Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide study in France. JAMA Ophthalmol. 2018;136(12):1352\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.3939.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"1002_CR22","first-page":"5697","volume":"59","author":"Z Tauqeer","year":"2018","unstructured":"Tauqeer Z, Storey P, Wolfe JD, et al. Endophthalmitis rates of ranibizumab in pre-filled syringes compared to vials. Invest Ophthalmol Vis Sci. 2018;59(9):5697.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1002_CR23","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/iae.0000000000002170","volume":"39","author":"I Loewenstein","year":"2019","unstructured":"Loewenstein I, Goldstein M, Moisseiev J, Moisseiev E. Accuracy and precision of intravitreal injections of anti-vascular endothelial growth factor agents in real life: what is actually in the syringe? Retina. 2019;39(7):1385\u201391. https:\/\/doi.org\/10.1097\/iae.0000000000002170.","journal-title":"Retina"},{"key":"1002_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","volume":"199","author":"PP Storey","year":"2019","unstructured":"Storey PP, Tauqeer Z, Yonekawa Y, et al. The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab. Am J Ophthalmol. 2019;199:200\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2018.11.023.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1002_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3928\/23258160-20210528-03","volume":"52","author":"DS Dhoot","year":"2021","unstructured":"Dhoot DS, Boucher N, Pitcher JD 3rd, Saroj N. Rates of suspected endophthalmitis following intravitreal injections in clinical practices in the United States. Ophthalmic Surg Lasers Imaging Retina. 2021;52(6):312\u20138. https:\/\/doi.org\/10.3928\/23258160-20210528-03.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"8","key":"1002_CR26","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41433-021-01523-z","volume":"35","author":"E Karatsai","year":"2021","unstructured":"Karatsai E, Chandra S, Fasolo S, Sivaprasad S, Hamilton R. Prefilled Eylea syringe: our recent experience. Eye (Lond). 2021;35(8):2083\u20135. https:\/\/doi.org\/10.1038\/s41433-021-01523-z.","journal-title":"Eye (Lond)"},{"issue":"12","key":"1002_CR27","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00417-021-05302-0","volume":"259","author":"M Krauthammer","year":"2021","unstructured":"Krauthammer M, Trabelsi E, Moisseiev E. Intravitreal air bubbles following intravitreal injections: a comprehensive analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259(12):3697\u2013702. https:\/\/doi.org\/10.1007\/s00417-021-05302-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"1002_CR28","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/02713683.2021.1874023","volume":"46","author":"M Pancholy","year":"2021","unstructured":"Pancholy M, Storey PP, Levin HJ, et al. Endophthalmitis following intravitreal anti-vascular endothelial growth factor therapy: changes in incidence and outcomes over a 9-year period. Curr Eye Res. 2021;46(9):1370\u20137. https:\/\/doi.org\/10.1080\/02713683.2021.1874023.","journal-title":"Curr Eye Res"},{"issue":"1","key":"1002_CR29","first-page":"2","volume":"244","author":"A Ugurlu","year":"2021","unstructured":"Ugurlu A. Comparison of the syringe preparation time for ranibizumab prefilled syringe versus bevacizumab, ranibizumab and aflibercept vial. Ophthalmologica. 2021;244(1):2.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1002_CR30","first-page":"2","volume":"244","author":"F Ula\u015f","year":"2021","unstructured":"Ula\u015f F, \u00d6z\u00e7il T, Bayrak A. Comparison of preparation and application duration of ranibizumab prefilled syringe, ranibizumab vial and aflibercept vial in real clinical setting. Ophthalmologica. 2021;244(1):2.","journal-title":"Ophthalmologica"},{"issue":"Suppl. 1","key":"1002_CR31","first-page":"A201","volume":"29","author":"C Aparicio Carre\u00f1o","year":"2022","unstructured":"Aparicio Carre\u00f1o C, G\u00e1ndara Ande A, F\u00f3rneas Sangil A, et al. Endophthalmitis after intravitreal injection with anti-angiogenic drugs: a rare but serious complication. Eur J Hosp Pharm. 2022;29(Suppl. 1):A201.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"1002_CR32","doi-asserted-by":"publisher","first-page":"18136","DOI":"10.1038\/s41598-022-23039-6","volume":"12","author":"VLS Dingerkus","year":"2022","unstructured":"Dingerkus VLS, Somfai GM, Kinzl S, Org\u00fcl SI, Becker MD, Heussen FM. Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes. Sci Rep. 2022;12(1):18136. https:\/\/doi.org\/10.1038\/s41598-022-23039-6.","journal-title":"Sci Rep"},{"issue":"1","key":"1002_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000518236","volume":"245","author":"M Finkelstein","year":"2022","unstructured":"Finkelstein M, Katz G, Zur D, Rubowitz A, Moisseiev E. The effect of syringe-filling technique on the risk for endophthalmitis after intravitreal injection of anti-VEGF agents. Ophthalmologica. 2022;245(1):34\u201340. https:\/\/doi.org\/10.1159\/000518236.","journal-title":"Ophthalmologica"},{"issue":"4","key":"1002_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/24741264231159011","volume":"7","author":"HL Feng","year":"2023","unstructured":"Feng HL, Abdelwahab S, Imam N, Astafurov K, Roth DB. Reduced incidence of intravitreal injection-related endophthalmitis with prefilled syringes. J Vitreoretin Dis. 2023;7(4):305\u20139. https:\/\/doi.org\/10.1177\/24741264231159011.","journal-title":"J Vitreoretin Dis"},{"key":"1002_CR35","doi-asserted-by":"publisher","unstructured":"Klaas JE, Bui V, Maierhofer N, et al. Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs the novel prefilled syringe formulation. Front Med. 2023;10:1295633. https:\/\/doi.org\/10.3389\/fmed.2023.1295633.","DOI":"10.3389\/fmed.2023.1295633"},{"issue":"5","key":"1002_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/24741264231191339","volume":"7","author":"AM Louis","year":"2023","unstructured":"Louis AM, Ali AM, Patel SB, et al. Impact of prefilled syringes and masking on postintravitreal injection endophthalmitis. J Vitreoretin Dis. 2023;7(5):382\u20138. https:\/\/doi.org\/10.1177\/24741264231191339.","journal-title":"J Vitreoretin Dis"},{"issue":"8","key":"1002_CR37","first-page":"2706","volume":"64","author":"NA Rana","year":"2023","unstructured":"Rana NA, Russell MW, Chalasani M, Sharma S, Singh RP, Muste J. Characterization of sustained increases in intraocular pressure after aflibercept in prefilled and vial draw syringes. Invest Ophthalmol Vis Sci. 2023;64(8):2706.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"1002_CR38","first-page":"3935","volume":"64","author":"C Rosanky","year":"2023","unstructured":"Rosanky C, Moon J, Khan S, Storey PP. Prefilled syringes and endophthalmitis following intravitreal injection of aflibercept. Invest Ophthalmol Vis Sci. 2023;64(8):3935.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1002_CR39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1177\/24741264231200735","volume":"7","author":"MW Russell","year":"2023","unstructured":"Russell MW, Chalasani M, Rana N, et al. Effect of prefilled vs vial-drawn syringes on sustained increases in intraocular pressure in patients treated with aflibercept. J Vitreoretin Dis. 2023;7(6):498\u2013503. https:\/\/doi.org\/10.1177\/24741264231200735.","journal-title":"J Vitreoretin Dis"},{"key":"1002_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/opth.S393519","volume":"17","author":"U Schmidt-Ott","year":"2023","unstructured":"Schmidt-Ott U, Fitzpatrick S, Hasanbasic Z, et al. Reported rates of intraocular inflammation with intravitreal aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022. Clin Ophthalmol. 2023;17:385\u201390. https:\/\/doi.org\/10.2147\/opth.S393519.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1002_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5731\/pdajpst.2017.008342","volume":"72","author":"AN Antoszyk","year":"2018","unstructured":"Antoszyk AN, Baker C, Calzada J, et al. Usability of the ranibizumab 0.5\u00a0mg prefilled syringe: human factors studies to evaluate critical task completion by healthcare professionals. PDA J Pharm Sci Technol. 2018;72(4):411\u20139. https:\/\/doi.org\/10.5731\/pdajpst.2017.008342.","journal-title":"PDA J Pharm Sci Technol"},{"key":"1002_CR42","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/OPTH.S207978","volume":"14","author":"M Schargus","year":"2020","unstructured":"Schargus M, Frings A. Issues with intravitreal administration of anti-VEGF drugs. Clin Ophthalmol. 2020;14:897\u2013904. https:\/\/doi.org\/10.2147\/OPTH.S207978.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1002_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jcjo.2020.01.015","volume":"55","author":"PP Storey","year":"2020","unstructured":"Storey PP, Patel D, Garg S. Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Can J Ophthalmol. 2020;55(4):286\u201392. https:\/\/doi.org\/10.1016\/j.jcjo.2020.01.015.","journal-title":"Can J Ophthalmol"},{"issue":"10","key":"1002_CR44","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/s41433-020-01211-4","volume":"35","author":"K Gallagher","year":"2021","unstructured":"Gallagher K, Raghuram AR, Williams GS, Davies N. Pre-filled aflibercept syringes-variability in expressed fluid volumes and a case series of transient central retinal artery occlusions. Eye (Lond). 2021;35(10):2899\u2013900. https:\/\/doi.org\/10.1038\/s41433-020-01211-4.","journal-title":"Eye (Lond)"},{"issue":"8","key":"1002_CR45","first-page":"457","volume":"62","author":"B Scruggs","year":"2021","unstructured":"Scruggs B, Lee DJ, Thomas M, Faridi A. Transient vision loss associated with aflibercept pre-filled syringes. Invest Ophthalmol Vis Sci. 2021;62(8):457.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"1002_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100115","volume":"2","author":"DJ Lee","year":"2022","unstructured":"Lee DJ, Scruggs BA, S\u00e1nchez E, Thomas M, Faridi A. Transient vision loss associated with prefilled aflibercept syringes: a case series and analysis of injection force. Ophthalmol Sci. 2022;2(2): 100115. https:\/\/doi.org\/10.1016\/j.xops.2022.100115.","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"1002_CR47","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jfo.2021.01.001","volume":"44","author":"A Couturier","year":"2021","unstructured":"Couturier A, Kodjikian L, Baillif S, et al. Treatment of exudative age-related macular degeneration: consensus of French experts for first-line treatment selection and the importance of long-term risk\/benefit ratio. J Fr Ophtalmol. 2021;44(7):937\u201346. https:\/\/doi.org\/10.1016\/j.jfo.2021.01.001.","journal-title":"J Fr Ophtalmol"},{"issue":"7","key":"1002_CR48","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/ceo.14125","volume":"50","author":"DJ Lee","year":"2022","unstructured":"Lee DJ, Scruggs BA, Faridi A, S\u00e1nchez E, Thomas M. Survey of intravitreal injection outcomes amongst ophthalmologists using pre-filled aflibercept syringes. Clin Exp Ophthalmol. 2022;50(7):803\u20135. https:\/\/doi.org\/10.1111\/ceo.14125.","journal-title":"Clin Exp Ophthalmol"},{"key":"1002_CR49","doi-asserted-by":"publisher","unstructured":"Raevis J. Re: Lee et al.: Transient vision loss associated with prefilled aflibercept syringes (Ophthalmol Sci. 2022;2:100115). Ophthalmol Sci. 2022;2(4):100199. https:\/\/doi.org\/10.1016\/j.xops.2022.100199.","DOI":"10.1016\/j.xops.2022.100199"},{"issue":"5","key":"1002_CR50","first-page":"434","volume":"24","author":"M Bjornstad","year":"2020","unstructured":"Bjornstad M, Kosinski T, Burlage R. Evaluation of the efficacy and superiority of different vial rubber closure disinfection techniques. Int J Pharm Compd. 2020;24(5):434\u20138.","journal-title":"Int J Pharm Compd"},{"issue":"6","key":"1002_CR51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4037\/ajcc1994.3.6.448","volume":"3","author":"T Buckley","year":"1994","unstructured":"Buckley T, Dudley SM, Donowitz LG. Defining unnecessary disinfection procedures for single-dose and multiple-dose vials. Am J Crit Care. 1994;3(6):448\u201351.","journal-title":"Am J Crit Care"},{"issue":"1","key":"1002_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40942-022-00375-3","volume":"8","author":"JM Guest","year":"2022","unstructured":"Guest JM, Malbin B, Abrams G, et al. Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe. Int J Retina Vitreous. 2022;8(1):27. https:\/\/doi.org\/10.1186\/s40942-022-00375-3.","journal-title":"Int J Retina Vitreous"},{"issue":"7","key":"1002_CR53","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41433-021-01646-3","volume":"36","author":"R Chopra","year":"2022","unstructured":"Chopra R, Preston GC, Keenan TDL, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye (Lond). 2022;36(7):1373\u20138. https:\/\/doi.org\/10.1038\/s41433-021-01646-3.","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-01002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:41:10Z","timestamp":1724409670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-01002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-01002-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joel Uzzan: Consultant and Investigator: Apellis, Bayer, Bausch\u2009+\u2009Lomb, F. Hoffmann-La Roche Ltd., Horus, and Novartis. Adam Mapani: Educational, travel, and research grants, advisory board, and speaker\u2019s fees: AbbVie, Alimera, Apellis, Bayer, Biogen, BVI, F. Hoffmann-La Roche Ltd., Gyroscope, Novartis, Scope International, and Veni-Vidi. Marloes Bagijn, Oliver Cox, and Insaf Saffar: Employee: F. Hoffmann-La Roche Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}